Business Context and Reporting Period
This Form 8-K is filed by Petra Acquisition, Inc. (the "Registrant") regarding its proposed business combination with Revelation Biosciences, Inc. The report covers events occurring between October 12, 2021, and December 15, 2021, with the filing date of December 17, 2021. The primary event reported is the extension of the deadline to consummate the business combination.
Key Financial Metrics and Liquidity
The filing details contributions made to the Registrant's Trust Account to fund the extension of the business combination deadline. No revenue, profit, or operating cash flow data is provided in this specific filing.
- Trust Account Contributions: Three separate contributions were made to the Trust Account, each in the aggregate amount of $160,957.
- Contribution Dates:
- October 12, 2021 (First extension)
- November 17, 2021 (Second extension)
- December 15, 2021 (Third extension)
- Per-Share Contribution: The filing states the contribution was $0.34 per share for the first extension and $0.034 per share for the subsequent two extensions for shares not redeemed.
- Debt and Margins: The filing text does not provide clear values for debt, margins, or liquidity outside of the Trust Account contributions.
Material Changes and Transaction Status
The material change reported is the sequential extension of the deadline to complete the merger with Revelation Biosciences:
- Original Deadline: October 13, 2021.
- First Extension: Extended to November 13, 2021 (approved by stockholders on October 8, 2021).
- Second Extension: Extended to December 13, 2021 (elected on November 13, 2021).
- Third Extension: Extended to January 13, 2022 (elected on December 13, 2021).
Each extension required a deposit into the Trust Account to maintain the value of the trust for public shareholders.
Outlook, Risks, and Management Commentary
Management highlights significant risks and uncertainties regarding the transaction and the future operations of the combined entity:
- Transaction Completion: Risks include the failure to obtain stockholder approval, failure to meet closing conditions, or termination of the Merger Agreement.
- Redemptions: There is uncertainty regarding the level of redemptions by Petra stockholders, which could materially reduce the cash proceeds available to Revelation Biosciences at closing. The filing notes that the Merger Agreement requires no minimum level of funding in the trust fund to close.
- Operational Risks: Risks include the successful completion of the RVL-CLR01 clinical study, enrollment delays, adverse safety events, and regulatory approval outcomes for product candidates (REVTx-99, REVTx-200, REVDx-501).
- Financial Sustainability: There is a risk that the company may not yield sufficient cash proceeds to support short-term operations and R&D efforts post-closing.
- Listing Status: Risk of inability to maintain Nasdaq listing following the business combination.
Investor Verification Checklist
- Verify the final amount of cash remaining in the Trust Account after accounting for any stockholder redemptions prior to the January 13, 2022 deadline.
- Confirm the status of the RVL-CLR01 clinical study and any recent data releases or safety concerns.
- Review the definitive proxy statement and Form S-4 for detailed terms of the merger and the specific interests of directors and executive officers.
- Assess whether the projected cash proceeds (assuming no redemptions) are sufficient to fund Revelation Biosciences' operational runway as described in the filing.
- Monitor for any amendments or terminations of the Merger Agreement before the new January 13, 2022 deadline.